{"id":1602,"date":"2021-02-17T16:00:56","date_gmt":"2021-02-17T16:00:56","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=1602"},"modified":"2026-02-23T23:07:31","modified_gmt":"2026-02-23T23:07:31","slug":"universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2021\/02\/17\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\/","title":{"rendered":"Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel (Contributed by Wu Jiang)"},"content":{"rendered":"

Our findings provide novel insight into the genetic screening of CRC patients in the era of multi-gene panel. Universal germline testing for cancer susceptibility genes should be recommend among all CRC patients diagnosed under age 70 years. It could discover substantially more individuals with hereditary cancer syndromes who would benefit from enhanced surveillance and tailored treatment. The testing panel could be optimized according to age of onset of CRC. A broad panel including genes from the additional set might be recommended to CRC patients older than 40 years to increase pathogenic variant detection rate and clarify inheritance risks. (https:\/\/jmg.bmj.com\/content\/early\/2021\/02\/09\/jmedgenet-2020-107230<\/a> )<\/p>\n","protected":false},"excerpt":{"rendered":"

Our findings provide novel insight into the genetic screening of CRC patients in the era of multi-gene panel. Universal germline testing for cancer susceptibility genes should be recommend among all CRC patients diagnosed under age 70 years. It could discover substantially more individuals with hereditary cancer syndromes who would benefit from enhanced surveillance and tailored […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1602","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"\nUniversal germline testing among patients with colorectal cancer: clinical actionability and optimised panel (Contributed by Wu Jiang) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2021\/02\/17\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel (Contributed by Wu Jiang) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"Our findings provide novel insight into the genetic screening of CRC patients in the era of multi-gene panel. Universal germline testing for cancer susceptibility genes should be recommend among all CRC patients diagnosed under age 70 years. It could discover substantially more individuals with hereditary cancer syndromes who would benefit from enhanced surveillance and tailored [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2021\/02\/17\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-17T16:00:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-23T23:07:31+00:00\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/02\\\/17\\\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/02\\\/17\\\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel (Contributed by Wu Jiang)\",\"datePublished\":\"2021-02-17T16:00:56+00:00\",\"dateModified\":\"2026-02-23T23:07:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/02\\\/17\\\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\\\/\"},\"wordCount\":121,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/02\\\/17\\\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/02\\\/17\\\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/02\\\/17\\\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\\\/\",\"name\":\"Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel (Contributed by Wu Jiang) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"datePublished\":\"2021-02-17T16:00:56+00:00\",\"dateModified\":\"2026-02-23T23:07:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/02\\\/17\\\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/02\\\/17\\\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/02\\\/17\\\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel (Contributed by Wu Jiang)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel (Contributed by Wu Jiang) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2021\/02\/17\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\/","og_locale":"en_US","og_type":"article","og_title":"Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel (Contributed by Wu Jiang) - JMG Contact blog","og_description":"Our findings provide novel insight into the genetic screening of CRC patients in the era of multi-gene panel. Universal germline testing for cancer susceptibility genes should be recommend among all CRC patients diagnosed under age 70 years. It could discover substantially more individuals with hereditary cancer syndromes who would benefit from enhanced surveillance and tailored [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2021\/02\/17\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\/","og_site_name":"JMG Contact blog","article_published_time":"2021-02-17T16:00:56+00:00","article_modified_time":"2026-02-23T23:07:31+00:00","author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/02\/17\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/02\/17\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel (Contributed by Wu Jiang)","datePublished":"2021-02-17T16:00:56+00:00","dateModified":"2026-02-23T23:07:31+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/02\/17\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\/"},"wordCount":121,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2021\/02\/17\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/02\/17\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\/","url":"https:\/\/blogs.bmj.com\/jmg\/2021\/02\/17\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\/","name":"Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel (Contributed by Wu Jiang) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"datePublished":"2021-02-17T16:00:56+00:00","dateModified":"2026-02-23T23:07:31+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/02\/17\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2021\/02\/17\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/02\/17\/universal-germline-testing-among-patients-with-colorectal-cancer-clinical-actionability-and-optimised-panel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel (Contributed by Wu Jiang)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=1602"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1602\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=1602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=1602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=1602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}